Below are the most recent publications written about "Ketoconazole" by people in Profiles.
-
George JC, Vedamurthy D, Bermudez M, Kennedy JW. Quiz Page October 2016: Severe Hypokalemia, Metabolic Alkalosis, and Malignancy. Am J Kidney Dis. 2016 10; 68(4):A17-A19.
-
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37.
-
Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43.
-
Kulkarni MM, Reddy N, Gude T, McGwire BS. Voriconazole suppresses the growth of Leishmania species in vitro. Parasitol Res. 2013 May; 112(5):2095-9.
-
Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemother Pharmacol. 2012 May; 69(5):1247-53.
-
Frederick DM, Jacinto EY, Patel NN, Rushmore TH, Tchao R, Harvison PJ. Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells. Toxicol In Vitro. 2011 Dec; 25(8):2113-9.
-
Dumaine R, Antzelevitch C. Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome? J Mol Cell Cardiol. 2006 Sep; 41(3):421-3.
-
Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, Shou M. Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J Pharmacol Exp Ther. 2005 May; 313(2):518-28.
-
McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, Brucker MJ, Miller-Stein C, Osborne B, Waldman S. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol. 1999 Dec; 39(12):1212-20.
-
Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, Shou M. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther. 1999 Nov; 291(2):749-59.